1. Home
  2. SOAR vs ARTL Comparison

SOAR vs ARTL Comparison

Compare SOAR & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Volato Group Inc.

SOAR

Volato Group Inc.

HOLD

Current Price

$0.23

Market Cap

5.3M

Sector

Finance

ML Signal

HOLD

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$4.02

Market Cap

4.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOAR
ARTL
Founded
2021
2011
Country
United States
United States
Employees
N/A
7
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3M
4.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SOAR
ARTL
Price
$0.23
$4.02
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
N/A
AVG Volume (30 Days)
6.2M
3.6M
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.28
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.19
$0.90
52 Week High
$4.36
$28.60

Technical Indicators

Market Signals
Indicator
SOAR
ARTL
Relative Strength Index (RSI) 40.89 42.93
Support Level $0.20 $3.05
Resistance Level $0.35 $4.97
Average True Range (ATR) 0.04 0.64
MACD 0.00 -0.39
Stochastic Oscillator 24.29 7.72

Price Performance

Historical Comparison
SOAR
ARTL

About SOAR Volato Group Inc.

Volato Group Inc operates an aircraft ownership program, provides ad-hoc charter flights, sells deposit products, and manages aircraft for owners in the private aviation industry. It offers fractional ownership, aircraft management, jet cards, deposit, and charter programs. The company's fractional programs provides flexible hours and a revenue share for owners in a fleet of HondaJets, optimized for missions of up to four passengers.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: